.Nature Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ state-of-the-art bosom cancer as well as active or even dependable brain metastases revealed consistent intracranial task and also systemic efficiency of T-DXd.